TABLE 2.
Validated lncRNA/miRNA pathways in in vivo and in vitro PD models.
| LncRNA | Target miRNA | Pathway | PD MODEL | Effects | References |
| GAS5 | miR-150 | FOSL1/PTEN/AKT/mTOR | MPP+ treated SH-SY5Y and N2a cells | Apoptosis and neuronal activity | Ma et al., 2022 |
| HOTAIR | miR-126-5p | RAB3IP |
In vivo In vivo |
Apoptosis and α-Syn-positive cells | Lin et al., 2019 |
| HOXA11-AS | miR-124-3p | FSTL1 | MPTP induced PD mice MPTP treated SH-SY5Y cells LPS induced BV-2 |
Neuroinflammation and neuronal apoptosis | Cao et al., 2021 |
| MALAT1 | miR-135b-5p | GPNMB | MPP+ SK-N-SH and SK-N-BE cells | Proliferation and apoptosis | Lv et al., 2021 |
| mir-124 | ?? | MPTP induced PD mice MPP+ treated SH-SY5Y cells |
Apoptosis | Liu et al., 2017 | |
| MIAT | miR-221-3p | TGFBR1/TGF-β1/Nrf2 | MPTP-induced PD mice MPP+ treated MN9D cells |
neuronal injury | Lang et al., 2022 |
| NEAT1 | miR-124-3p | PDE4B | MPP+ treated SH-SY5Y cells | Cell viability, cytotoxicity and inflammation | Chen M. Y. et al., 2021 |
| miR-124 | KLF4 | MPP+ treated SH-SY5Y cells | Apoptosis | Liu et al., 2020 | |
| NORAD | miR-204-5p | SLC5A3 | MPP+ treated SK-N-SH and SK-N-AS cells | Neuroprotection | Zhou S. et al., 2020 |
| OIP5-AS1 | miR-137 | NIX | MPP+ treated SH-SY5Y cells | Mitochondrial autophagy | Zhao et al., 2022 |
| SNHG1 | miR-216a-3p | BAX | MPP+ treated SK-N-SH cells | Apoptosis | Wang H. et al., 2021 |
| SNHG7 | miR-425-5p | TRAF5/NF-κB | Rot-mediated PD rat SH-SY5Y cells |
Inflammation and oxidative stress | Zhang et al., 2021 |
| SNHG14 | miR-135b-5p | KPNA4 | MPP+ treated SK-N-SH cells | Neuronal injury | Yuan et al., 2022 |
| TUG1 | miR-152-3p | PTEN | MPTP-induced PD mice MPP+ treated SH-SY5Y cells |
Apoptosis, oxidative stress, and neuroinflammation | Zhai et al., 2020 |
| UCA1 | miR-651-5p | KPNA4 | MPP+ treated SH-SY5Y cells | Apoptosis, inflammation, oxidative stress and neuronal damage | Hao et al., 2023 |
AKT, protein kinase B; BAX, Bcl2 associated X trotein; FOSL1, Fos ligand1; FSTL1, Follistatin-like 1; GAS5, growth arrest-specific 5; GPNMB, glycoprotein non-metastatic melanoma protein B; HOTAIR, HOX Transcript Antisense Intergenic RNA; HOXA11-AS, Homeobox A11 antisense RNA; KLF4, Kruppel-like factor 4; KPNA4, karyopherin subunit alpha 4; NF-K b, nuclear factor kappa-light-chain-enhancer of activated B cells; MALAT, metastasis-associated lung adenocarcinoma transcript 1; MIAT, myocardial infarction-associated transcript; MPP+, N-methyl-4-phenylpyridinium; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; m-TOR, mammalian target of rapamycin; NEAT1, nuclear enriched abundant transcript 1; Nrf2, nuclear factor E2-related factor 2; NORAD, RNA Activated by DNA Damage; OIP5-AS1, Opa Interacting Protein 5antisense RNA; PDE4B, phosphodiesterase 4B; PTEN, Phosphatase and tensin homolog; RAB3IP, RAB3A Interacting Protein; SLC5A3, solute carrier family 5 member 3; SNHG, small nucleolar RNA host gene; TGF-β1, transforming growth factor-β1; TGFBR1, TGFB receptor 1; TRAF5, tumor necrosis factor receptor-associated factor; TUG1, taurine upregulated gene 1; UCA1, urothelial carcinoma-associated 1.